CoDiagnostics (CODX)
(Delayed Data from NSDQ)
$1.29 USD
-0.02 (-1.53%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $1.30 +0.01 (0.78%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Co-Diagnostics, Inc. [CODX]
Reports for Purchase
Showing records 41 - 60 ( 81 total )
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Sequential Revenue Growth in 4Q20; Reiterate Buy; Raising PT to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
3Q20 Financial Results Reported; Reiterate Buy; Lowering PT to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
COVID-19 Testing Market Remains Attractive; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
New Patent Enhances CoPrimer Technology Protection; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
2Q20 Financial Results; Reiterate Buy; Modulating PT to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
EUA Granted for Partner?s Saliva COVID-19 Test; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Domestic COVID-19 Surge Boosts Testing Demand; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Detection of SARS-CoV-2 in Cancer Tissue Published; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
1Q20 Results; 2Q20 Sales Eclipse Forecast; Reiterate Buy; Raising PT to $35
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Healthcare - Coronavirus Vol. 31: Novartis Goes All in on Hydroxychloroquine for COVID-19
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
CoPrimer-based COVID-19 Test Validated for Saliva Analysis; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Additional Manufacturing Capacity Contracted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
FDA Issues Emergency Use Authorization to COVID-19 Test; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Co-Diagnostics, Inc.
Industry: Medical Services
COVID-19 Test Completes Clinical Evaluation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Indian Joint Venture Gets COVID-19 Diagnostic Test License; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
U.S. Coronavirus Test Shipments Slated to Expand; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Co-Diagnostics Goes to Washington; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Co-Diagnostics, Inc.
Industry: Medical Services
Coronavirus Test Shipped to U.S. and International Markets; Reiterate Buy; Raising PT to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y